

.

.

2

Rapid Response[™]

ETG Test Panel (Urine)

Product Insert

A rapid visual immunoassay for the qualitative detection of ETG in human urine specimens.

For forensic use only.

Intended Use

The Rapid Response[™] ETG Test Panel (Urine) is a rapid visual immunoassay for the qualitative, presumptive detection of ETG in human urine specimens at the cut-off concentrations listed below:

Parameter	Calibrator	Cut-off (ng/mL)
ETG	Ethyl Glucuronide	500/1000

The Rapid Response[™] ETG Test Panel (Urine) test is used to obtain visual qualitative result and is intended to assist in the determination of drug compliance.

This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC/MS) or Liquid Chromatography/ Mass Spectrometry (LC/MS) are the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug test result, particularly when preliminary positive results are indicated.

Introduction

Ethyl glucuronide (ETG) is a minor non-oxidative metabolite of ethyl alcohol formed by the in vivo conjugation of ethanol with glucuronic acid with UDP glucuronosyl transferase. ETG is a product of metabolic process about of Ingested alcohol (ethanol) rapidly metabolized in the body, which is excreted in the blood, hair and urine. By using The Rapid Response[™] ETG Test Panel (Urine) can detect ETG in urine, confirming the consumption of alcohol. The ETG metabolite remains in the body longer and therefore has a more useful window of detection of 8 to 80 hours. ETG testing is an excellent option for zero-tolerance alcohol consumption or rehabilitation programs.

Principle

The Rapid Response™ ETG Test Panel (Urine) is an immunoassay based on the principle of competitive binding.

The base of each test strip membrane has a colored antibody colloidal gold conjugate pad specific to the target drug or metabolite. Further along the test membrane, the test region (T) is pre-coated with a drug-protein conjugate specific to the target drug or metabolite. The control region (C) is precoated with a different antigen or antibody that is not specific to the target drug or metabolite.

As the base of the test strip comes in contact with urine, the specimen migrates upwards by capillary action. This movement transports the specimen and colored antibody-colloidal gold conjugate across the test strip membrane to the test and control regions.

In the absence of the targeted drug or metabolite in the urine specimen, the colored antibody-colloidal gold conjugate will bind to the drug-protein conjugate immobilized on the test region. This binding forms a visible colored line that indicates a negative result

If present in the urine specimen, the targeted drug or metabolite will compete with the drug-protein conjugate, immobilized on the test region, for the limited binding sites on the colored antibody-colloidal gold conjugate. When a sufficient concentration of the drug or metabolite (the designated cut-off level) is present, it will bind to all the colored antibody-colloidal gold conjugate preventing it from binding to the drug-protein conjugate in the test region. In the absence of the antibody-colloidal gold conjugate binding to the test region, no colored line will appear. The absence of a colored band in the test region indicates a positive result.

Regardless of the presence and absence of the target metabolite or drug, the

antibody-colloidal gold conjugate will also bind to the non-specific antibody immobilized on the control region. This binding forms a visible colored band which indicates the test has been performed properly. If the control band does not appear the test results should be considered invalid, and the test strip discarded.

Reagents

Each test consists of a reagent Single Panel mounted in a plastic housing. The amount of each antigen and/or antibody coated on the Single Panel is less than 0.001 mg for antigen conjugates and goat anti-rabbit IgG antibodies, and less than 0.0015 mg for antibody components.

The control zone of each test contains goat anti-rabbit IgG antibody. The test zone of each test contains drug-bovine protein antigen conjugate, and the conjugate pad of each test contains monoclonal anti-drug antibody and rabbit antibody-colored particle complex.

- For forensic use only.
- Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged. Do not reuse tests.
- This kit contains products of animal origin. Certified knowledge of the origin and/or sanitary state of the animals does not completely guarantee the absence of transmissible pathogenic agents. It is therefore, recommended that these products be treated as potentially infectious, and handled by observing usual safety precautions (e.g., do not ingest or inhale).
- Avoid cross-contamination of specimens by using a new specimen collection container for each specimen obtained.
- Read the entire procedure carefully prior to testing.
- Do not eat, drink or smoke in the area where specimens and kits are handled. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow standard procedures for the proper disposal of specimens. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Humidity and temperature can adversely affect results.
- Used testing materials should be discarded in accordance with local, state and/or federal regulations.

Materials

Materials provided

Test Panel Package insert

Materials required but not provided

- Positive and negative controls Timer
 - Centrifuge

Storage and Stability

- The kit should be stored at 35.6-86°F (2-30°C) until the expiry date printed on the sealed pouch or canister.
- The test must remain in the sealed pouch or closed canister until use. Do not freeze.
- Kits should be kept out of direct sunlight.
- Care should be taken to protect the components of the kit from contamination. Do not use if there is evidence of microbial contamination or precipitation Biological contamination of dispensing equipment, containers or reagents can lead to false results.

Collection and Storage of Specimens


The Rapid Response[™] ETG Test Panel (Urine) is intended for use with human urine specimens only.

- Urine collected at any time of the day may be used. .
- Urine specimens must be collected in clean, dry containers.
- Turbid specimens should be centrifuged, filtered, or allowed to settle and only . the clear supernatant should be used for testing.
- Perform testing immediately after specimen collection. Do not leave specimens at room temperature for prolonged periods. Urine specimens may be stored at 35.6-46.4°F (2-8°C) for up to 2 days. For long term storage, specimens should be kept below -4° F (-20°C).
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Avoid repeated freezing and thawing of specimens.
- If specimens are to be shipped, pack them in compliance with all applicable regulations for transportation of etiological agents.

Test Procedure


Bring tests, specimens, and/or controls to room temperature (59-86°F; 15-30°C) before use it if the specimens are refrigerated.

- 1. Remove the test from its sealed pouch and use it as soon as possible. To obtain a best result, the assay should be performed within one hour. (See illustration
 - Remove the protective cap before dipping the test panel. (See illustration 2).
- Hold the Single Panel at the handle with the product name imprints. Do not 3. touch the membrane part of the Single Panel to avoid contamination.
- 4. Dip the test Single Panel vertically in the urine specimen for at least 10-15 seconds. Do not pass the maximum line (MAX) on the test Single Panel when immersing the Single Panel. As the test begins to work, you will see color move across the membrane. (See illustration 3),
- 5. Take the Single Panel out of the specimen afterwards and place it on a nonabsorbent flat surface. Start the timer and wait for the colored line(s) to appear. 5 Minutes after collection: The result should be read at 5 minutes. Do not interpret the result after 10 minutes. (See illustration 4).



Results Interpretation






с

NOTE:

2.

NEGATIVE: Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T) for the drug in guestion. A negative result indicates that the drug or metabolite concentration is below the detectable level.





- Reading a Faint Line: The intensity of color in the test region (T) may vary depending on the concentration of analytes present in the specimen. Therefore, any shade of color in the test region (T) should be considered negative. Please note that this is a qualitative test only and cannot determine the concentration of analytes in the specimen.
- Invalid Results: Insufficient specimen volume, incorrect operating procedure or expired tests are the most likely reasons for control band failure.

Quality Control

- Internal procedural controls are included in the test. A colored band appearing in the control region (C) is considered an internal positive procedural control, confirming sufficient specimen volume and correct procedural technique.
- External controls are not supplied with this kit. It is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

Limitations

- The Rapid Response[™] ETG Test Panel (Urine) is for forensic use only, and should 1. be only used for the qualitative detection of ETG.
- 2. This assay provides a preliminary analytical test result only. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) has been established as the preferred confirmatory method by the National Institute on Drug Abuse (NIDA). Clinical consideration and professional judgment should be applied to any test result, particularly when preliminary positive results are indicated
- 3. There is a possibility that technical or procedural errors as well as other substances and factors may interfere with the test and cause false results.
- 4 Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. Therefore, please preclude the possibility of urine adulteration prior to testing.
- 5. A positive result indicates the presence of a ETG only, and does not indicate or measure intoxication
- 6. A negative result does not at any time rule out the presence of ETG in urine, as they may be present below the minimum detection level of the test.
- 7. This test does not distinguish between ETG and certain medications.

Performance Characteristics

Accuracy

5 Minutes

The accuracy of the Rapid Response ETG Test Panel (Urine) was compared and checked against commercially available tests with a threshold value at the same cutoff levels. Urine samples taken from volunteers claiming to be non-users were examined under both tests. The results of ETG 500 and ETG 1000 were 89.2% and 99.1%, respectively,

Reproducibility

The reproducibility of the Rapid Response ETG Test Panel (Urine) was verified by blind tests performed at four different locations. Samples with ETG concentrations at 50% of the cut-off were all determined to be negative, while samples with ETG concentrations at 200% of the cut-off were all determined to be positive.



c 🗖

Precautions



REF Catalogue #

Precision

Test precision was determined by blind tests with control solutions. Controls with ETG concentrations at 50% of the cut-off yielded negative results, and controls with ETG concentrations at 150% of the cut-off yielded positive results.

Specificity

The following tables list the concentrations of compounds (ng/mL) above which the Rapid Response ETG Test Panel (Urine) identified positive results at 5 minutes.

ETG 500-related compounds	Concentration (ng/ml)
Ethyl Glucuronide	500
Ethanol	>100,000
D-Glucuronic Acid	>100,000
Morphine-3-b-D-glucuronide	>100,000
ETG 500-related compounds	Concentration (ng/ml)
Ethyl Glucuronide	1,000
Ethanol	>100,000
D-Glucuronic Acid	>100,000
Morphine-3-b-D-glucuronide	>100.000

The following compounds yielded negative results up to a concentration of 100 $\mu g/mL$:

(-)-Ephedrine	(+)-Naproxen
(+/-)-Ephedrine	4-Dimethyllaminoantiyrine
Acetaminophen	Acetone
Albumin	Amitriptyline
Ampicillin	Aspartame
Aspirin	Benzocaine
Bilirubin	b-Phenylethyl-amine
Caffeine	Chloroquine
Chlorpheniramine	Creatine
Dextromethorphan	Dextrorphan tartrate
Dopamine	Erythromycin
Ethanol	Furosemide
Glucose	Guaiacol Glyceryl Ether
Hemoglobin	Ibuprofen
Imipramine	Isoproterenol
Lidocaine	Oxalic Acid
Penicillin-G	Pheniramine
Phenothiazine	Procaine
Protonix	Pseudoephedrine
Quinidine	Ranitidine
Sertraline	Tyramine
Vitamin C (Ascorbic Acid)	Trimeprazine
Venlafaxine	Methadone

Bibliography

- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd ed. Davis: Biomedical Publications; 1982.
- Hawks RL, Chiang CN, eds. Urine Testing for Drugs of Abuse. Rockville: Department of Health and Human Services, National Institute on Drug Abuse; 1986.
- Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs. 53 Federal Register; 1988.
- McBay AJ. Drug-analysis technology--pitfalls and problems of drug testing. Clin Chem. 1987 Oct; 33 (11 Suppl): 33B-40B.

 Gilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan; 1980.

0 20				
30	Store between 2°C to 30°C	52	Use by	
200			0000.09	

LOT	Lot Number

i



